Swiss National Bank Atreca, Inc. Transaction History

Swiss National Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$2.87 - $6.29 $152,684 - $334,628	-53,200 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$7.82 - $13.8 $66,470 - $117,300	-8,500 Reduced 13.78%	53,200 $453,000
Q1 2021 May 07, 2021	BUY	$13.0 - $19.34 $27,300 - $40,614	2,100 Added 3.52%	61,700 $946,000
Q4 2020 Feb 05, 2021	BUY	$13.03 - $17.09 $13,030 - $17,090	1,000 Added 1.71%	59,600 $963,000
Q3 2020 Nov 09, 2020	BUY	$12.67 - $23.19 $397,838 - $728,166	31,400 Added 115.44%	58,600 $819,000
Q2 2020 Aug 05, 2020	BUY	$12.52 - $23.45 $340,544 - $637,840	27,200 New	27,200 $579,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.